Aptinyx Reports First Quarter 2020 Financial Results and Highlights
14 mai 2020 16h03 HE
|
Aptinyx Inc.
Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020 Cash balance of $121 million expected to support planned operations...
Aptinyx to Report First Quarter Financial Results on Thursday, May 14, 2020
30 avr. 2020 08h47 HE
|
Aptinyx Inc.
EVANSTON, Ill., April 30, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
30 mars 2020 16h01 HE
|
Aptinyx Inc.
Initiated four Phase 2 clinical studies based on compelling prior data Actions taken on ongoing clinical studies due to COVID-19 pandemic Strong cash position following recently completed common...
Aptinyx to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 30, 2020
18 mars 2020 16h01 HE
|
Aptinyx Inc.
EVANSTON, Ill., March 18, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
27 févr. 2020 16h30 HE
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
Zhittya Genesis Medicine Releases Latest White Paper Highlighting its Potential Breakthrough Drug Treatment for Chronic Depression
19 févr. 2020 12h00 HE
|
Zhittya Genesis Medicine Inc
LAS VEGAS, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya” or the “Company”), announced that its latest White Paper, which details results on its...
Aptinyx to Present at Upcoming Investor Conferences
19 févr. 2020 08h37 HE
|
Aptinyx Inc.
EVANSTON, Ill., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease
30 janv. 2020 07h07 HE
|
Aptinyx Inc.
EVANSTON, Ill., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option
14 janv. 2020 16h01 HE
|
Aptinyx Inc.
EVANSTON, Ill., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Neurostimulation Devices Market To Reach USD 12.7 Billion By 2026 | Reports And Data
08 janv. 2020 09h53 HE
|
Reports and Data
New York, Jan. 08, 2020 (GLOBE NEWSWIRE) -- According to the current analysis of Reports and Data, the global Neurostimulation Devices market was valued at USD 4.98 Billion in 2018 and is expected...